Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

bluebird bio lodges counterclaim against Spark Therapeutics

bluebird bio lodges counterclaim against Spark Therapeutics

bluebird bio has launched a counterclaim against Spark Therapeutics after the latter initiated a dispute a few months ago, according to Boston Business Journal. ... Spark Therapeutics is also developing a gene therapy for the potential treatment of

Latest news

More from news
Approximately 18 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

    Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Mind+Matter Mind+Matter

    Spark Therapeutics, Superdrug, Thornton &Ross, Vetoquinol, VMIC,  Zogenix.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...

Quick links